相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC
Dong Wang et al.
PEERJ (2019)
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study
Elena Marinelli Busilacchi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel
Yoshimasa Miyagawa et al.
CLINICAL BREAST CANCER (2018)
Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy
Zhaoqing Du et al.
PLOS ONE (2018)
Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation
Fabian J. Bolte et al.
GASTROENTEROLOGY (2017)
Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
A. Rebonato et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)
Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis
Lejia Sun et al.
ONCOTARGET (2017)
Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection
Kazuto Tajiri et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma
Ai-bin Zhang et al.
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B (2016)
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
Andrea Casadei Gardini et al.
ONCOTARGET (2016)
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Andrew Gabrielson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
Yoram S. Baum et al.
ASIAN JOURNAL OF UROLOGY (2016)
World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma
Catherine de Martel et al.
HEPATOLOGY (2015)
The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization
Daniel C. Sukato et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2015)
Distinct Functions of Neutrophil in Cancer and Its Regulation
Zvi Granot et al.
MEDIATORS OF INFLAMMATION (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go?
Hashem B. El-Serag et al.
HEPATOLOGY (2014)
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
Mei-Ling Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Neutrophil-to-Lymphocyte Ratio as a Predictor of Outcomes for Patients With Hepatocellular Carcinoma: A Western Perspective
Kevin M. Sullivan et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Leonardo Gomes da Fonseca et al.
MEDICAL ONCOLOGY (2014)
Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection
Weijia Liao et al.
TRANSLATIONAL ONCOLOGY (2014)
Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Megan E. McNally et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice
Pascale Buchmann et al.
VACCINE (2013)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
Antonia Busse et al.
EUROPEAN JOURNAL OF CANCER (2011)
CURRENT CONCEPTS Hepatocellular Carcinoma
Hashem B. El-Serag
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Alan P. Venook et al.
ONCOLOGIST (2010)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Hepatocellular carcinoma pathogenesis: from genes to environment
Paraskevi A. Farazi et al.
NATURE REVIEWS CANCER (2006)
Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study
JA Davila et al.
GASTROENTEROLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
分享论文
